Literature DB >> 8174112

Down-regulation of bcl-2 by p53 in breast cancer cells.

S Haldar1, M Negrini, M Monne, S Sabbioni, C M Croce.   

Abstract

bcl-2 and p53 gene products have been both linked to programmed cell death pathways. We have analyzed several human breast cancer cell lines for the expression of bcl-2 and p53. We found an inverse correlation between the expression of the two proteins. The result suggested that mutant p53 could substitute for bcl-2 function in breast cancer cells and that could also down-regulate bcl-2 expression. We found, indeed, that overexpression of a mutant p53 (mut 175) in MCF-7 cells could induce down-regulation of bcl-2 both at protein and mRNA level. However, the promoter region of the human bcl-2 gene does not contain the negative regulatory element responsible for the down-regulation. If this mechanism will be proved also for the wild-type p53 allele, it may disclose a possible mechanism for p53-induced apoptosis: down-regulation of bcl-2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8174112

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  103 in total

Review 1.  Regulation of p53 and its targets during involution of the mammary gland.

Authors:  D J Jerry; J Pinkas; C Kuperwasser; E S Dickinson; S P Naber
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-04       Impact factor: 2.673

2.  Cell proliferation and DNA breaks are involved in ultraviolet light-induced apoptosis in nucleotide excision repair-deficient Chinese hamster cells.

Authors:  Torsten R Dunkern; Bernd Kaina
Journal:  Mol Biol Cell       Date:  2002-01       Impact factor: 4.138

3.  Expression of bcl-2 Protein in Breast Carcinoma with Correlation to Expression of p53 Protein and Clinicopathological Factors.

Authors: 
Journal:  Breast Cancer       Date:  1996-12-20       Impact factor: 4.239

4.  Oestrogen prevents cardiomyocyte apoptosis by suppressing p38α-mediated activation of p53 and by down-regulating p53 inhibition on p38β.

Authors:  Han Liu; Ali Pedram; Jin Kyung Kim
Journal:  Cardiovasc Res       Date:  2010-08-19       Impact factor: 10.787

5.  Bcl-2 expression and allelic loss of the p53 gene in gastric carcinomas.

Authors:  M Saegusa; Y Takano; Y Kamata; J Okayasu
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

6.  Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.

Authors:  Rit Vatsyayan; Jyotsana Singhal; Lokesh Dalasanur Nagaprashantha; Sanjay Awasthi; Sharad S Singhal
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

7.  DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a.

Authors:  Yalu Zhou; Ricardo E Perez; Lei Duan; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2018-03-13       Impact factor: 4.742

8.  Significance of p53, Bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer.

Authors:  Mansour Al-Moundhri; V Nirmala; K Al-Mawaly; S Ganguly; I Burney; A Rizvi; C Grant
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

9.  Proteasome inhibitors suppress the protein expression of mutant p53.

Authors:  Marianna Halasi; Bulbul Pandit; Andrei L Gartel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma.

Authors:  S E Coupland; N Bechrakis; A Schüler; I Anagnostopoulos; M Hummel; N Bornfeld; H Stein
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.